Open AccessThe Antithrombotic Effect of Recombinant Neorudin on Thrombi
Author(s) -
Yubin Liu,
Lin Zhang,
Xingchen Zhou,
Ying Zhou,
Yun Liu,
Can Zheng,
Xiao Xu,
Pan Geng,
Chunyan Hao,
Zhuanyou Zhao,
Cheng-Feng Wu,
Jian Jin
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s353088
Subject(s) - antithrombotic , recombinant dna , fibrinolytic agent , medicine , chemistry , biochemistry , gene
Recombinant neorudin (EPR-hirudin, EH) was developed through the addition of an EPR (Glu-Pro-Arg) peptide to the amino terminus of hirudin, which can be recognized and cut by coagulation factors XIa (FXIa) and/or Xa (FXa). In this study, the low-bleeding antithrombotic effects of EH were evaluated utilizing experimental models of thrombosis in rabbits and rats to provide a test basis for clinical trials.